Concord Medical Services Holding Limited is classed by the SEC under Services-Offices & Clinics of Doctors of Medicine (industry code 8011), based in Chaoyang District, Beijing, CN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $65 million and a loss of $54 million (its filed statements).
Usage businessServices-Offices & Clinics of Doctors of MedicineChaoyang District, Beijing, CNfilings since 20097 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8011, Services-Offices & Clinics of Doctors of Medicine); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.5 out of ten, 7 of 9 metrics filed and 2 estimated: past 5.1 out of ten, present 3.8 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 7.2 out of ten. 1 warning event since 2017; the latest 2021-04-30. 72nd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 1.4 out of ten. +0.1% a year over 10 filed years; profitable in 0 of 10. 14th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 9.4 out of ten. CrossAssetData estimate 9.4/10, confidence 35 of 100 (one part). 94th percentile among 9 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.7 out of ten. ROE -5%: lost 5¢ per shareholder dollar. Leverage 72%: owes 72¢ per asset dollar. 47th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 2.2 out of ten. bottom 22% of 9 in its family; net margin -20.2%. 22nd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 6 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 1.1 out of ten. bottom 11% of 9 in its family for room to expand. 11th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.8 out of ten. bottom 48% of 8 in its family for growth drivers. 48th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 6 in its family for expectations against reality. 69th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-29 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-22. Filings on record since 2009. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Hospital 81%, Network 19%. As tagged in its annual report (Form 20-F, filed 2026-04-29).
Who runs it
Yang, Jianyu (Chief Executive Officer); Shi, Botao (Interim CFO); Jiang, Wei (nmn) (Chief Financial Officer); Cheng, Zheng (director); Liu, Hongzhong (director); Yu, Wayne (nmn) (director); Zhang, Liping (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.